Evotec Sells API Manufacturing Site to Monacum Partners, Streamlining Focus on Core Growth Areas

Evotec Sells API Manufacturing Site to Monacum Partners, Streamlining Focus on Core Growth Areas

(IN BRIEF) Evotec SE has sold its chemical API-focused manufacturing site, Evotec DS GmbH, to Monacum Partners as part of its “Priority Reset” strategy to focus on core growth areas. The Halle/Westphalia-based facility, now renamed DAPIN GmbH, will continue its operations under the new ownership, which is committed to supporting the facility’s growth and retaining its workforce.

(PRESS RELEASE) HAMBURG, 5-Nov-2024 — /EuropaWire/ — Evotec SE has completed the sale of its chemical API manufacturing facility, Evotec DS GmbH, in Halle/Westphalia, to private equity firm Monacum Partners GmbH. This divestment aligns with Evotec’s “Priority Reset” strategy, introduced in April 2024, which aims to concentrate resources on core growth areas and optimize its operational structure. The Halle-based site, a specialized CDMO focused on chemical APIs, intermediates, and building blocks, offers comprehensive services from development to commercial-scale production.

Under the new ownership, Evotec DS will operate as DAPIN GmbH (Deutsche API & Intermediates), with Monacum Partners committed to supporting and growing the business. All existing operations and employees will be retained, ensuring continuity and further development of the facility’s capabilities. The financial details of the transaction were not disclosed.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

About Monacum Partners
Monacum Partners is a Munich based private equity firm, focused on repositioning of European headquartered businesses. The core of Monacum Partners strategy, is acquiring underperforming companies with significant operational improvement potential and support them through proven turnaround playbooks, implemented by Monacum Partners’ highly experienced operational team. For additional information please go to www.monacumpartners.com.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contacts:

Investor Relations:
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

Media Relations:
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com

SOURCE: Evotec